The antibody–drug conjugate ifinatamab deruxtecan (I-DXd) showed clinically meaningful responses in pretreated patients with extensive-stage small cell lung cancer (ES-SCLC), according to an interim analysis of the Phase 2 IDeate-Lung01 study.
Cannabist Closes Convertible Note Offering
The Cannabist Company Announces Closing of US$25.75 Million Private Placement Offering of 9% Senior Secured Convertible Debentures Due 2027US$6.25 Million of total will be issued